News
This Is Arguably the Single Best Stock to Buy Right Now
What's the single best stock to buy right now? Ask five different investors and you'll probably get five different answers.
The problem, of course, is that defining what makes a given candidate the
Sarepta Therapeutics (SRPT) Q2 2023 Earnings Call Transcript
Sarepta Therapeutics (NASDAQ: SRPT)Q2 2023 Earnings CallAug 02, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Karyopharm Therapeutics (KPTI) Q2 2023 Earnings Call Transcript
Karyopharm Therapeutics (NASDAQ: KPTI)Q2 2023 Earnings CallAug 02, 2023, 8:00 a.m. ET
Operator
Source Fool.com
Why Shares of Blueprint Medicines Are Falling Wednesday
Shares of Blueprint Medicines (NASDAQ: BPMC) were down more than 12% as of 12:45 p.m. on Wednesday after the healthcare company announced second-quarter earnings. The stock is still up more than 27%
This Deep Value Stock Is a Strong Buy
Value investing can be a powerful strategy. Buying businesses for less than they are worth can limit your risk of significant capital losses, and it can increase your chances of future upside.
The
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Exelixis (EXEL) Q2 2023 Earnings Call Transcript
Pfizer (PFE) Q2 2023 Earnings Call Transcript
Pfizer (PFE) Q2 2023 Earnings Call Transcript
Vertex Pharmaceuticals (VRTX) Q2 2023 Earnings Call Transcript
Vertex Pharmaceuticals (NASDAQ: VRTX)Q2 2023 Earnings CallAug 01, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Vertex Pharmaceuticals (VRTX) Q2 2023 Earnings Call Transcript
Vertex Pharmaceuticals (NASDAQ: VRTX)Q2 2023 Earnings CallAug 01, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Vertex Pharmaceuticals (VRTX) Q2 2023 Earnings Call Transcript
Vertex Pharmaceuticals (NASDAQ: VRTX)Q2 2023 Earnings CallAug 01, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Merck (MRK) Q2 2023 Earnings Call Transcript
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
3 Magnificent High-Yield Dividend Stocks to Buy Hand Over Fist in August
Any time is a good time for income investors to buy dividend stocks. But certain times are better than others for specific stocks.
I think that's the case for several great picks with a new month
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Biogen's (NASDAQ: BIIB) biggest problem in recent times has been growth. The biotech giant's multiple sclerosis (MS) portfolio is facing more and more generic competition, and that's resulted in
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Biogen's (NASDAQ: BIIB) biggest problem in recent times has been growth. The biotech giant's multiple sclerosis (MS) portfolio is facing more and more generic competition, and that's resulted in
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Biogen's (NASDAQ: BIIB) biggest problem in recent times has been growth. The biotech giant's multiple sclerosis (MS) portfolio is facing more and more generic competition, and that's resulted in
Why Novavax Stock Zoomed 13% Higher on Monday
News of a fresh COVID-19 surge sent numerous stockholders into the shares of vaccine maker Novavax (NASDAQ: NVAX) on the first trading day of the week. As a result, Novavax's shares popped more than
Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen
Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) will soon likely be going head to head in the market for therapies that treat Alzheimer's disease. Both drug developers see the market for such
Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen
Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) will soon likely be going head to head in the market for therapies that treat Alzheimer's disease. Both drug developers see the market for such
Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen
Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) will soon likely be going head to head in the market for therapies that treat Alzheimer's disease. Both drug developers see the market for such
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Could This Stock Be the Next Biotech Buyout?
Shares of Reata Pharmaceuticals (NASDAQ: RETA) recently jumped about 54% higher in a single trading session. This biotech stock was already way up this year thanks to the recent approval of its
Could This Stock Be the Next Biotech Buyout?
Shares of Reata Pharmaceuticals (NASDAQ: RETA) recently jumped about 54% higher in a single trading session. This biotech stock was already way up this year thanks to the recent approval of its